<DOC>
	<DOCNO>NCT02955160</DOCNO>
	<brief_summary>This Phase 1 first-in-human , randomize , control , observer-blinded study 2-arm parallel design . Healthy adult age 18 49 year age history pneumococcal vaccination randomize equally receive either single intramuscular dose multivalent pneumococcal conjugate vaccine license tetanus , diphtheria , acellular pertussis combination vaccine ( Tdap ) ( control group ) .</brief_summary>
	<brief_title>A Phase 1 , Randomized , Controlled , Observer-blinded Trial Evaluate Safety Immunogenicity Multivalent Pneumococcal Conjugate Vaccine Healthy Adults Aged 18 49 Years</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Male female adult 18 49 year age . 2 . Healthy adult determine medical history , physical examination , laboratory screening , clinical judgment eligible study . 3 . Negative serum pregnancy test female subject childbearing potential . 1 . Baseline laboratory test result outside normal reference range consider clinically significant . 2 . History severe adverse reaction and/or severe allergic reaction ( eg , anaphylaxis ) associate vaccine . 3 . History cultureproven invasive disease cause S pneumoniae . 4 . Previous vaccination license investigational pneumococcal vaccine , plan receipt study participation . 5 . Vaccination diphtheria , pertussis , tetanuscontaining vaccine ( ) 12 month investigational product administration , plan receipt study participation . 6 . Male subject female subject childbearing potential unwilling unable use highly effective method contraception outline protocol duration study participation least 6 month last dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>